Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bextra Label Changes Under Discussion After Hypersensitivity Reactions

Executive Summary

Pfizer and Pharmacia are in discussions with FDA regarding safety-related label changes for Bextra, Pfizer said during its third quarter earnings call Oct. 16
Advertisement

Related Content

Pfizer/Pharmacia Bextra Adds Hypersensitivity And Skin Reaction Warnings
Pfizer/Pharmacia Bextra Adds Hypersensitivity And Skin Reaction Warnings
Merck Arcoxia 6,000-Patient Trial Will Study GI, Cardiac Events
Celebrex Label Update Has CV Profile Similar To NSAIDs, No New GI Safety
Celebrex Label Update Has CV Profile Similar To NSAIDs, No New GI Safety
Vioxx Label Balances CV Risk With GI Safety: Can Merck Reverse Damage?
Advertisement
UsernamePublicRestriction

Register

PS040639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel